This time last year Pfizer projected $15 billion in Covid vaccine sales in 2021. Actual sales ($36.8 billion) came in 2.45 times higher, making the Pfizer Covid vaccine the top-selling pharmaceutical product ever in a single year (by a huge margin). Pfizer only projects out revenues once they have an agreement or contract.
Based on existing deals, Pfizer is currently projecting $22 billion in sales for Paxlovid in 2022. Assuming we get a repeat of what happened last year with the vaccine, we are potentially looking at $54 billion in Paxlovid revenue in 2022. Pfizer plans to manufacture 120 million courses of Paxlovid this year. Assuming $54 billion in Paxlovid sales, that comes to $450 per course. The current contracts with the US govt pay $530 each for 20 million courses to be delivered by Sep 2022.
Whatever Pfizer makes from Paxlovid is on top of the $32 billion in sales projected from the Covid vaccine in 2022.
Bottom line: 2022 is shaping up to be another spectacular year for Pfizer. Paxlovid has the potential to break the single-year sales record set last year by the Pfizer Covid vaccine.
Comments